Neobacitracine (Bacitracin, Neomycin)

Bacitracin blocks bacterial cell‑wall synthesis by inhibiting the dephosphorylation of bactoprenol, while neomycin binds to the 30S ribosomal subunit, preventing protein synthesis. Together they produce a rapid bactericidal effect against a broad range of Gram‑positive and Gram‑negative organisms when applied locally.

The dosage of Neobacitracine is determined by the prescribing healthcare professional based on the infection site, severity and patient factors. The prescriber will specify the amount, frequency and duration of application appropriate for each indication.

Safety data for Neobacitracine in pregnancy and lactation are limited. It should only be used when the potential benefit justifies any possible risk to the fetus or infant, and the decision should be made by a qualified healthcare provider.

To order Neobacitracine, submit an enquiry on the product page at gnhindia.com, indicating the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Neobacitracine combines two agents—bacitracin and neomycin—offering a broader spectrum than single‑agent products such as mupirocin. This dual mechanism can be advantageous for mixed bacterial flora, but it also carries a higher risk of allergic reactions compared with some newer monotherapy agents.

Neobacitracine should be stored at room temperature, below 25 °C, in its original packaging. Keep the container tightly closed, protect it from moisture and direct sunlight, and ensure it is out of reach of children.

Neobacitracine is applied topically to the affected area. For ear infections, a few drops are placed in the external canal; for skin, a thin layer is spread over the lesion; for nasal use, a small amount is applied inside the nostrils; for ocular infections, the recommended number of drops is instilled in the conjunctival sac.

Serious adverse reactions, although rare, include anaphylaxis, Stevens‑Johnson syndrome, ototoxicity with prolonged ear use, nephrotoxicity after extensive systemic absorption, and severe contact dermatitis. Patients should seek immediate medical attention if they experience signs of a severe allergic reaction or unexpected systemic symptoms.

Neobacitracine is contraindicated in individuals with a known hypersensitivity to bacitracin, neomycin or any component of the formulation. It should also be avoided in patients with extensive broken skin where systemic absorption could be significant, and in those receiving other ototoxic medications unless closely monitored.